FDA Approves Talvey (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

HORSHAM, Pa., Aug. 10, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Talvey™ (talquetamab-tgvs), a first-in-class...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news